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Abstract
Background: Multimorbidity is associated with mortality and service use, with specific types of multimorbidity
having differential effects. Additionally, multimorbidity is often negatively associated with participation in research
cohorts. Therefore, we set out to identify clusters of multimorbidity patients and how they are differentially
associated with mortality and service use across age groups in a population-representative sample.
Methods: Linked primary and secondary care electronic health records contributed by 382 general practices in
England to the Clinical Practice Research Datalink (CPRD) were used. The study included a representative set of
multimorbid adults (18 years old or more, N = 113,211) with two or more long-term conditions (a total of 38
conditions were included). A random set of 80% of the multimorbid patients (N = 90,571) were stratified by age
groups and clustered using latent class analysis. Consistency between obtained multimorbidity phenotypes,
classification quality and associations with demographic characteristics and primary outcomes (GP consultations,
hospitalisations, regular medications and mortality) was validated in the remaining 20% of multimorbid patients
(N = 22,640).
Results: We identified 20 patient clusters across four age strata. The clusters with the highest mortality comprised
psychoactive substance and alcohol misuse (aged 18–64); coronary heart disease, depression and pain (aged 65–
84); and coronary heart disease, heart failure and atrial fibrillation (aged 85+). The clusters with the highest service
use coincided with those with the highest mortality for people aged over 65. For people aged 18–64, the cluster
with the highest service use comprised depression, anxiety and pain. The majority of 85+-year-old multimorbid
patients belonged to the cluster with the lowest service use and mortality for that age range. Pain featured in 13
clusters.
Conclusions: This work has highlighted patterns of multimorbidity that have implications for health services. These
include the importance of psychoactive substance and alcohol misuse in people under the age of 65, of co-morbid
depression and coronary heart disease in people aged 65–84 and of cardiovascular disease in people aged 85+.
Keywords: Multimorbidity phenotype, Chronic conditions, Latent class analysis, Pattern recognition, Validation, Age
stratification
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Background
As a result of improved life expectancy and ageing popu-
lations, a growing number of individuals are living with
multimorbidity, i.e. more than one long-term condition
[1, 2]. Multimorbidity has been recognised as a global
challenge for health care management [3], and it is esti-
mated by the Health Foundation that 14 million individ-
uals in England have multimorbidity, with over a third of
these having more than four long-term conditions [4]. Pa-
tients with multimorbidity also account for the majority of
primary care consultations, prescriptions and hospitalisa-
tions in the UK [5]. However, current clinical specialities,
guidelines, quality improvement strategies and quality of
care metrics are organised around single diseases [6], and
treatments of multiple conditions are rarely coordinated,
resulting in insufficient or even conflicting care [6, 7].
Patients with multimorbidity have a diverse range of
diseases, needs and outcomes [4, 5, 8]. Identifying and
characterising groups of multimorbid patients that share
similar patterns of long-term conditions might facilitate
an improvement in their healthcare. For example, such
an approach might aid the development of effective
strategies for early diagnosis and prevention of multi-
morbidity and allow for a better design and delivery of
targeted interventions [1, 9]. Several systematic reviews
have found common multimorbidity clusters involving
cardiovascular-metabolic conditions, mental health and
musculoskeletal disorders [10, 11]. However, existing
evidence has important limitations. The two largest
studies of specific multimorbidity groups in the UK have
used UK Biobank data where participants are healthier
(i.e. less multimorbid), smoke and drink less and are
from less socioeconomically deprived areas than the
overall population [12–14]. Second, most previous stud-
ies have focused on older populations (aged 60+); few
have provided age-stratified clusters [10, 11, 15], leaving
scarce evidence for the younger multimorbid population.
Third, multimorbidity clusters composed of more than
two conditions have not been well profiled mostly due
to non-representative and smaller samples [1, 10, 11].
Fourth, there is substantial heterogeneity in the number
of conditions considered (often less than 20) and in the
statistical methods. Most studies focused on grouping
diseases rather than patients, where each disease can
only go into one cluster and so it is not straightforward
to relate patients to outcomes in order to facilitate
patient-centred policy-making [16]. Commonly used
clustering methods were exploratory approaches such as
factor analysis and hierarchical clustering [10, 17], where
results were highly sensitive to the subjective choice of
metrics [18]. Finally, the validity and generalisability of
cluster solutions in new samples is important for
decision-making but is often ignored in the current lit-
erature [10, 11].
This study aims to identify, validate and study the out-
comes of age-stratified clusters of multimorbid adult pa-
tients in a large representative sample of UK patients.
Towards this end, we used a comprehensive list of 38
long-term conditions [5] and a robust model-based
probabilistic approach, latent class analysis [18].
Methods
Data source
Our analysis used the Clinical Practice Research Data-
link (CPRD)-GOLD database where anonymised and
longitudinal primary care clinical data are contributed
by UK general (family) practices (GP) who use the Vi-
sion health record system [19]. CPRD has been validated
to be representative of the UK population for age, sex
and ethnicity [19, 20]. Patients’ GP records were linked
with hospitalisation data (Hospital Episodes Statistics,
HES), all-cause mortality data (Office for National Statis-
tics, ONS) and area-based (1000–1500 people per area
around patients’ home) socioeconomic deprivation data
(Index of Multiple Deprivation, IMD); these linked data
were available for approximately 75% of English prac-
tices in CPRD. The protocol for this study (16_057RA2)
was approved scientifically and ethically by the CPRD
Independent Scientific Advisory Committee.
Study population
Data on a random selection of individuals were acquired
from CPRD (the same individuals studied in Cassell
et al. [5]). Patients aged 18 years and above with valid
registered status in a practice with data classified by
CPRD as “up-to-standard” in January 2012 [19] were in-
cluded in the study. We chose the year 2012 to allow
complete ascertainment of 5-year mortality. Addition-
ally, we required that their practice allowed linkage to
ONS, IMD and HES, resulting in the inclusion of only
English practices.
Patient and public involvement
There was no patient or public involvement in this
study.
Statistical software
Data analysis was performed in R 3.4.4. R package names
are given in the following sections where appropriate (in
brackets and italics); for example, memory-efficient
packages were used to extract data for analysis in R (ff,
CALIBERdatamanage). For transparency and reproduci-
bility, all analysis scripts and code lists are available from
https://github.com/Kiddle-group.
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Definition of patient characteristics, morbidities and
outcomes
Morbidities in this study were defined as binary variables
(present or not) based on the classification of LTCs in
primary care developed by Barnett et al. [8]. This tax-
onomy attempted to include all conditions “likely to be
chronic (defined as having significant impact over at
least the most recent year) and with significant impact
on patients in terms of need for chronic treatment, re-
duced function, reduced quality of life and risk of future
morbidity and mortality”, and was developed for use in
UK primary care electronic health record research and
has been adapted for use in CPRD [5]. The specific defi-
nitions for each LTC are based on the UK Read code
system and electronic prescription data coded using
CPRD’s prodcode, giving a total of 38 LTCs (https://
www.phpc.cam.ac.uk/pcu/cprd_cam/codelists/v11/). The
LTCs used in this study largely match the only other
large sample size UK multimorbidity cluster study [13].
Two sets of outcome variables related to service use
and mortality were defined. NHS service utilisation or
treatment burden was measured by three variables over
the 12-month period after January 2012: primary care
consultations (consultations with any clinician in the pri-
mary care team), the number of all-type hospitalisation
spells (defined by discharge dates) and the count of
regular medications (at least four prescriptions in a year
by counting the unique British National Formulary
(BNF) codes). All-cause mortality at 2 and 5 years was
extracted from ONS data.
Patient characteristics that were considered in this
study include gender, age groups (stratified into 18–44,
45–64, 65–84 and 85+ years) in 2012, last recorded pre-
2012 body mass index (BMI), last recorded pre-2012
smoking status (current, never and ex-smokers) and so-
cioeconomic deprivation measured by quintiles of IMD
across the UK (1 for the least socioeconomically de-
prived quintile of areas and 5 for the most). Gender and
age were determined in a straightforward manner from
the CPRD-GOLD patient table. BMI and smoking status
were extracted from the CPRD-GOLD clinical and add-
itional tables using CPRD entity type 13 (BMI), CPRD
entity type 4 (smoking status) and a smoking status Read
code list from Jennifer Quint (Imperial College London)
which is available at https://github.com/Kiddle-group.
Statistical analysis
This study aims to identify clusters of multimorbid patients
using patterns of co-existing long-term conditions. We used
latent class analysis (LCA) (poLCA) to assign all patients to
non-overlapping clusters (i.e. each patient is assigned to only
one cluster) in a data-driven fashion [21, 22]. Compared to
other exploratory clustering methods (e.g. factor analysis,
hierarchical clustering [11, 23]), LCA is a model-based
probabilistic clustering approach that is not sensitive to the
rotation of factors and does not require any subjective
choice of “distance measures” for multimorbidity patterns
[18, 24]. This greatly enhances the reproducibility and stabil-
ity of the latent class solutions. Clustering patients rather
than diseases allows diseases to belong to multiple clusters
and more naturally allows the characteristics and outcomes
of clusters to be studied. As a result, each derived patient
cluster has a unique and probabilistic multimorbidity
phenotype profile where members do not necessarily need
to have all conditions.
Guided by simulation studies [25], the optimal number
of latent classes was decided using a combination of sta-
tistics (Bayesian Information Criteria (BIC), sample size-
adjusted BIC, log-likelihood ratio test, entropy for classi-
fication quality) and clinical judgement. Within our
datasets, conditions are present (i.e. recorded) or not by
definition, and so missing data methods were not needed
for cluster analysis. More details on a technical review of
commonly used clustering methods, the LCA method-
ology and application of selection statistics are provided
in Additional file 2: section 3.
To account for the different nature of multimorbidity
clusters at different ages, four age strata (18–44, 45–64,
65–84, 85+ years) were chosen. We derived the cluster
solution and performed post hoc statistical tests in a
stratified (by age strata) random sample of the multi-
morbid population that contained 80% of the patients
(i.e. training set). Separate LCAs were performed for
each stratum, and each patient allocated to a single mul-
timorbidity cluster. For ease of interpretation, clusters
were labelled by their three most distinctive conditions
whose difference in prevalence between cluster and age
strata were the highest (see Additional file 2: table 1 for
full details of conditions). To quantify the association be-
tween outcomes, multimorbidity clusters and patient
demographics, generalised linear models were fitted (see
Additional file 2: section 5). In the models for service
use and health outcomes, the multimorbidity cluster
with the lowest impact on the outcomes was taken as
reference. For these models, individuals with missing
data for last pre-2012 recording of smoking status or BMI
represented a small percentage (< 5%) of the population,
and so were excluded from the generalised linear models.
Additional sensitivity analyses also using complete-case
analysis were performed for the entire sample where the
non-multimorbid patient group (which had higher miss-
ingness of smoking and BMI) was taken as reference (see
Additional file 2: tables 16-19).
Assessment of the stability of morbidity clusters
To assess the stability of age-stratified multimorbidity
clusters, LCAs were repeated in the remaining 20% of
the population (i.e. test set), fixing the number of
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clusters to match that learned from the training set [26].
We employed three methods to indirectly validate our
cluster solutions (a direct approach was not possible as
clusters were unobserved). First, to check the consistency
between disease profiles for 38 LTCs in the training and
test sets, each cluster in the test set was matched (using
two criteria for robustness) with a corresponding cluster
in the training set. Matched cluster pairs were selected
such that Jensen–Shannon distance [27] (JSD; a measure
of the divergence between disease profiles) is the smallest
and the bivariate Pearson’s correlation coefficient [28] (the
degree to which two disease profiles co-vary) is the highest
(Additional file 2: tables 4a, b). Second, entropy measures
[25] (for classification quality) computed in the training
and test sets were expected to be similar. Finally, stability
was further assessed by observing in the training and test
sets similar associations (in terms of size, direction and
statistical significance) between clusters, patient demo-
graphics and outcome variables. For more details, see
Additional file 2: section 4.
Results
Characteristics of the study population
A total of 391,669 patients were included in the study, of
which 49% and 22% had none or only one long-term
condition respectively (see Table 1 for patient demo-
graphics). Females, older individuals and those from
areas of greater socioeconomic deprivation had a higher
prevalence of multimorbidity.
Among the multimorbid patients (i.e. those with
more than one long-term condition, N = 113,211,
29%), all unique combinations of conditions were less
than 1% prevalent in the total population with the
most prevalent 20 containing only pairs of conditions
(Additional file 2: table 2). This together with the
large number of unique combinations of conditions
(Additional file 2: table 3) indicated that multimorbid-
ity patterns were highly heterogeneous. Stratified by
age strata, Table 2 shows that multimorbidity in the
younger population (18–44) was more common in
areas with greater socioeconomic deprivation while
for older groups, the pattern is reversed.
Multimorbidity clusters and outcomes
For ease of reference, we refer to each cluster by its lead
or key conditions (i.e. one or three conditions, respect-
ively, whose cluster-specific prevalence is highest, and
higher than their overall prevalence in their respective
age group).
Table 1 Demographic characteristics of the whole population (N = 391,669). For ordinal variables, median and first (Q1) and third
(Q3) quartiles are reported. For categorical variables, counts and percentages are reported
Demographics N (%) No. of morbidities, median [Q1–Q3] Multimorbid patients (%)
All patients 391,669 (100) 1 [0–2] 28.9
Gender
Male 192,929 (49.3) 0 [0–2] 26.0
Female 198,740 (50.7) 1 [0–2] 31.7
Age group (years)
18–24 32,007 (8.2) 0 [0–0] 4.7
25–34 60,501 (15.4) 0 [0–1] 7.9
35–44 68,688 (17.5) 0 [0–1] 13.1
45–54 74,734 (19.1) 0 [0–1] 20.5
55–64 60,323 (15.4) 1 [0–2] 34.4
65–74 49,427 (12.6) 2 [1–3] 53.6
75–84 31,262 (8.0) 3 [1–4] 73.6
85+ 14,727 (3.8) 4 [2–5] 83.6
Socioeconomic status
1 (least deprivation) 90,730 (23.2) 1 [0–2] 27.1
2 87,734 (22.4) 1 [0–2] 28.5
3 81,569 (20.8) 1 [0–2] 29.1
4 71,424 (18.2) 1 [0–2] 29.3
5 (greatest deprivation) 60,212 (15.4) 1 [0–2] 31.4
Independence test for demographics and multimorbidity
Gender vs multimorbidity: χ2 (1) = 1573.4, p < 0.001
Age group vs multimorbidity: χ2 (7) = 100,340.1, p < 0.001
IMD vs multimorbidity: χ2 (4) = 337.4, p < 0.001
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These clusters differ across age strata, both in terms of
the number of clusters per strata and main components
within each cluster (Table 3 and Additional file 2: figures
1-4). The association between multimorbidity clusters
and outcomes (service use and mortality) remained sig-
nificant (p < 0.01 in almost all clusters) after stratifying
by age strata, controlling for socioeconomic deprivation,
BMI and smoking behaviour (Additional file 2: tables 8–
11). Results for the distribution of outcomes (i.e. median,
interquartile range (IQR)) are shown in Table 4. Covari-
ate-adjusted incidence rate ratios (aIRRs) for service util-
isation and odds ratios (OR) for mortality derived from
generalised linear models are available in Additional file
2: tables 8–15 (adjusted covariates were gender, socio-
economic deprivation, smoking status, BMI and age).
Age strata: 18–44 years old
Five clusters were uncovered in the 18–44 age strata
(Additional file 2: figures 1 & 5), whose lead conditions
were depression (the most common cluster, 32% of pa-
tients in strata), pain (23%), asthma (20%), irritable
bowel syndrome (18%) and psychoactive substance mis-
use (7%). Those in the cluster whose three key condi-
tions were depression (within-cluster prevalence 100%),
anxiety (41%) and pain (31%) were found to have the
highest use of primary care consultations (median 12
[IQR 5–20] in a year). This cluster had an aIRR of pri-
mary care consultations of 1.35 (95% confidence interval
(CI) 1.28–1.43) in comparison with the cluster with the
lowest service use and mortality (whose lead condition
was irritable bowel syndrome).
Those in the cluster whose three key conditions were
pain (36%), hearing loss (30%) and hypertension (23%)
were found to have the highest hospital admission rates
(an average of 0.6 visits in a year) and the highest count
of regular medicines (median 1 [IQR 0–4] unique drug
classes in a year). This corresponded to an aIRR for hos-
pitalisations of 1.04 [95% CI 0.90–1.20] and an aIRR for
regular medicines of 1.87 [95% CI 1.74–2.02] relative to
the cluster with the lowest service use and mortality.
The highest mortality in this age range was found in
the least prevalent (7%) multimorbidity cluster whose
three key conditions were psychoactive substance misuse
(75%), alcohol problems (42%) and depression (24%)
(3.9% mortality in 5 years). This level of mortality was
18 times higher than that of individuals in the same age
range without multimorbidity (0.2%). This cluster was
predominantly male (72%), came from socioeconomi-
cally deprived areas (63% from the most deprived 40% of
UK areas) and with high smoking rates (76% current
smokers).
Age strata: 45–64 years old
In the 45–64 age strata, LCA revealed five clusters (Add-
itional file 2: figures 2 & 6), whose lead conditions were
hypertension (the most common cluster, 37% of patients
in strata), irritable bowel syndrome (24%), depression
(22%), asthma (12%) and alcohol problems (4%). Those
Table 2 Characteristics of multimorbid patients (N = 113,211). For continuous and ordinal variables, median and first (Q1) and third
(Q3) quartiles are reported. For categorical variables, counts and percentages are reported
Demographic characteristics Across age strata
(N = 113,211)
Age 18–44 years
(N = 15,306)
Age 45–64 years
(N = 36,097)
Age 65–84 years
(N = 49,494)
Age 85+ years
(N = 12,314)
Female (%) 63,072 (56) 9422 (62) 19,690 (55) 25,952 (52) 8008 (65)
No. of morbidities, median [Q1–Q3] 3 [2–4] 2 [2–3] 2 [2–3] 3 [2–4] 4 [3–6]
Age, median [Q1–Q3] 66 [53–77] 37 [30–41] 56 [51–61] 74 [69–79] 89 [86–91]
BMI
Median [Q1–Q3] 27 [24–31] 26 [23–31] 28 [25–33] 27 [24–31] 25 [22–28]
Missing (%) 5788 (5) 1571 (10) 1462 (4) 1540 (3) 1215 (10)
Smoking status (%)
Current smoker 21,586 (19) 5641 (37) 9140 (25) 6160 (12) 645 (5)
Never smoker 55,145 (49) 6789 (45) 17,040 (47) 24,042 (49) 7274 (59)
Ex-smoker 36,265 (32) 2821 (18) 9869 (27) 19,251 (39) 4324 (35)
Missing 215 (0.19) 55 (0.36) 48 (0.13) 41 (0.08) 71 (0.58)
Index of multiple deprivation in quintiles (%)
1 (least deprivation) 24,624 (22) 2647 (17) 7333 (20) 11,722 (24) 2922 (24)
2 25,027 (22) 2738 (18) 7668 (21) 11,667 (24) 2954 (24)
3 23,700 (21) 2969 (19) 7352 (20) 10,612 (21) 2767 (22)
4 20,934 (18) 3316 (22) 6862 (19) 8645 (17) 2111 (17)
5 (greatest deprivation) 18,926 (17) 3636 (24) 6882 (19) 6848 (14) 1560 (13)
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in the cluster whose three key conditions were depres-
sion (93%), pain (53%) and anxiety (31%) had the highest
number of primary care consultations (median 14 [IQR
7–23] in a year, aIRR = 1.52 [95% CI 1.47–1.58]), hos-
pital admission rates (an average of 0.6 visits in a year,
aIRR = 1.31 [95% CI 1.31–1.44]) and regular medications
(median 4 [IQR 2–7], aIRR = 2.37 [95% CI 2.29–2.46]).
As in the younger age strata, the least prevalent multi-
morbidity cluster (4%) had the highest death rate (13%
in 5 years, OR = 1.08 [95% CI 1.07–1.10]); its key condi-
tions were alcohol problems (62%), psychoactive sub-
stance misuse (42%) and pain (28%). Again, this cluster
was characterised by being typically male smokers from
areas of high socioeconomic deprivation. Pain as a co-
morbidity was represented in all the clusters in this age
group.
Age strata: 65–84 years old
Six clusters were found in the 65–84 age strata
(Additional file 2: figures 3 & 7), whose lead condi-
tions were hypertension (the most common cluster,
41% of patients in strata), hearing loss (22%), depres-
sion (14%), coronary heart disease (11%), chronic ob-
structive pulmonary disease (8%) and pain (5%). The
least prevalent multimorbidity cluster (5%), whose
key conditions were pain (81%), coronary heart dis-
ease (53%) and depression (45%), had the highest use
of primary care consultations (median 23 [IQR 14–
35] in a year, aIRR = 1.92 [95% CI 1.82–2.02]), hos-
pital admissions (an average of 1.6 visits in a year,
aIRR = 2.15 [95% CI 1.94–2.40]), regular medicines
(median 11 [IQR 8–14], aIRR = 2.88 [95% CI 2.88–
3.00]) and death rates (39% mortality in 5 years).
Table 3 Descriptions of the derived clusters of multimorbid patients for each age strata. Clusters are ordered by sizes from the
largest to the smallest. Key conditions are the three estimated to be most distinctive in the cluster (where the difference between
within-cluster prevalence and prevalence in age strata is the largest). For the number of morbidities, median and first (Q1) and third
(Q3) quartiles are reported. For other categorical variables, percentages are reported. Greater deprivation denotes top 40% of IMD
(categories 4 and 5)
Three key conditions (prevalence) Patients
(%)
No. of morbidities
(median [Q1–Q3])
Female
(%)
Greater
deprivation (%)
Current
smokers (%)Lead condition (%) Subsidiary conditions (%)
Age 18–44 years
Depression (100%) Anxiety (41%), pain (31%) 32 2 [2–3] 66 50 46
Pain (36%) Hearing loss (30%), hypertension (23%) 23 2 [2–3] 52 46 27
Asthma (100%) IBS (26%), depression (20%) 20 2 [2–3] 63 41 29
IBS (100%) Depression (29%), hearing loss (21%) 18 2 [2–3] 77 37 28
PSM (75%) Alcohol (42%), depression (24%) 7 2 [2–3] 28 63 76
Age 45–64 years
Hypertension (76%) Diabetes (37%), pain (25%) 37 2 [2–3] 42 38 20
IBS (40%) Hearing loss (29%), pain (28%) 24 2 [2–3] 64 29 20
Depression (93%) Pain (53%), anxiety (31%) 22 3 [2–5] 68 46 35
Asthma (100%) Pain (24%), COPD (16%) 12 2 [2–3] 61 35 20
Alcohol (62%) PSM (42%), pain (28%) 4 3 [2–4] 31 57 63
Age 65–84 years
Hypertension (100%) Diabetes (31%), pain (27%) 41 3 [2–4] 54 30 10
Hearing loss (40%) Prostate disorder (21%), IBS (3%) 22 3 [2–4] 48 25 9
Depression (56%) Pain (56%), anxiety (23%) 14 4 [3–5] 72 33 15
CHD (54%) Diabetes (32%), atrial fibrillation (29%) 11 4 [3–5] 30 33 12
COPD (57%) Asthma (49%), pain (33%) 8 3 [2–5] 50 40 24
Pain (81%) CHD (53%), depression (45%) 5 7 [7–9] 54 43 16
Age 85+ years
Hypertension (72%) Hearing loss (39%), diabetes (18%) 58 3 [2–4] 61 30 5
Pain (64%) Depression (41%), constipation (24%) 23 5 [4–6] 80 30 5
CHD (61%) Atrial fibrillation (53%), heart failure (49%) 11 7 [6–8] 60 30 4
Asthma (48%) COPD (48%), pain (44%) 8 5 [4–6] 59 30 8
IBS irritable bowel syndrome, PSM psychoactive substance misuse (not alcohol), CHD coronary heart disease, COPD chronic obstructive pulmonary disease
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Age strata: above 85 years old
The 85+ age stratum was composed of four clusters
(Additional file 2: figures 4 & 8), whose lead conditions
were hypertension (the most common, 58% of patients
in strata), pain (23%), heart failure (11%) and asthma
(8%). The majority of patients (58%) fitted within a clus-
ter whose key conditions were hypertension (72%), hear-
ing loss (39%) and diabetes (18%). The cluster with the
majority of patients had the lowest mortality (50% 5-year
mortality), as well as the least number of conditions
(median 3 [IQR 2–4] morbidities), and the least health
care utilisation (roughly half the GP contacts, hospitali-
sations and regular medicines of the cluster whose lead
condition was “coronary heart disease”). The cluster with
the highest mortality, GP contact, hospitalisations and
repeat prescriptions comprised a trio of cardiac
Table 4 Mortality and health service utilisation by patient clusters in each age stratum. Clusters are ordered by the highest to the
lowest mortality. The non-multimorbid cluster contains patients with zero or only one long-term condition. The number of GP
consultations, hospitalisations and repeat prescriptions (by counting the number of unique BNF codes that were in repeated
prescriptions at least four times) are measured in 1 year after January 2012. Both mean and median are reported because they
highlight different aspects of skewed distributions, especially in relation to hospitalisations and prescriptions
Three key conditions (prevalence) 2-year
mortality
(%)
5-year
mortality
(%)
No. of GP
contacts in a
year (mean,
median [Q1–
Q3])
No. of
hospitalisations
in a year
(mean, median
[Q1–Q3])
No. of unique
medicine on
repeat
prescriptions
in a year
(mean,
median [Q1–
Q3])
Lead condition (%) Subsidiary conditions (%)
Age 18–44 years
PSM (75%) Alcohol (42%), depression (24%) 1.8 3.9 10.7, 7 [1–16] 0.4, 0 [0–0] 1.3, 0 [0–2]
Pain (36%) Hearing loss (30%), hypertension (23%) 1.0 2.7 11.9, 9 [3–17] 0.6, 0 [0–0] 2.5, 1 [0–4]
Depression (100%) Anxiety (41%), pain (31%) 0.9 1.8 14.5, 12 [5–20] 0.4, 0 [0–0] 2.4, 2 [0–3]
Asthma (100%) IBS (26%), depression (20%) 0.2 0.6 11.3, 9 [4–16] 0.4, 0 [0–0] 1.9, 1 [0–3]
IBS (100%) Depression (29%), hearing loss (21%) 0.2 0.4 10.6, 8 [3–15] 0.4, 0 [0–0] 1.2, 0 [0–2]
Non-multimorbid 0.1 0.2 3.7, 1 [0–5] 0.2, 0 [0–0] 0.2, 0 [0–0]
Age 45–64 years
Alcohol (62%) PSM (42%), pain (28%) 4.5 12.5 10.7, 8 [2–16] 0.5, 0 [0–1] 2.4, 1 [0–4]
Depression (93%) Pain (53%), anxiety (31%) 2.4 5.8 16.7, 14 [7–23] 0.6, 0 [0–1] 5.1, 4 [2–7]
Hypertension (76%) Diabetes (37%), pain (25%) 1.6 4.4 11.5, 9 [4–16] 0.5, 0 [0–0] 4.1, 4 [1–6]
IBS (40%) Hearing loss (29%), pain (28%) 1.3 3.0 10.5, 8 [3–15] 0.5, 0 [0–0] 2.0, 1 [0–3]
Asthma (100%) Pain (24%), COPD (16%) 1.0 2.7 12.6, 10 [5–17] 0.4, 0 [0–0] 3.4, 3 [1–5]
Non-multimorbid 0.4 1.3 4.4, 2 [0–6] 0.2, 0 [0–0] 0.5, 0 [0–0]
Age 65–84 years
Pain (81%) CHD (53%), depression (45%) 16.2 39.2 26.3, 23 [14–35] 1.6, 1 [0–2] 10.7, 11 [8–14]
CHD (54%) Diabetes (32%), atrial fibrillation (29%) 11.3 28.8 16.8, 14 [6–24] 1.1, 0 [0–1] 5.9, 6 [3–8]
COPD (57%) Asthma (49%), pain (33%) 9.2 25.5 15.7, 13 [6–22] 0.8, 0 [0–1] 5.5, 5 [2–8]
Depression (56%) Pain (56%), anxiety (23%) 8.4 20.9 17.3, 14 [8–23] 0.8, 0 [0–1] 5.9, 6 [3–8]
Hypertension (100%) Diabetes (31%), pain (27%) 4.7 13.2 12.4, 10 [4–17] 0.6, 0 [0–1] 4.5, 4 [2–7]
Hearing loss (40%) Prostate disorder (21%), IBS (3%) 4.4 11.1 13.2, 11 [5–19] 0.7, 0 [0–1] 3.3, 3 [1–5]
Non-multimorbid 1.9 6.6 6.4, 4 [0–9] 0.3, 0 [0–0] 1.2, 0 [0–2]
Age 85+ years
CHD (61%) Atrial fibrillation (53%), heart failure (49%) 37.7 70.8 21.9, 18 [9–31] 1.5, 1 [0–2] 8.0, 8 [5–11]
Pain (64%) Depression (41%), constipation (24%) 31.1 62.9 17.3, 15 [7–24] 0.8, 0 [0–1] 6.7, 7 [4–10]
Asthma (48%) COPD (48%), pain (44%) 28.0 56.5 19.6, 17 [9–27] 1.1, 0 [0–2] 6.9, 7 [4–10]
Hypertension (72%) Hearing loss (39%), diabetes (18%) 20.9 49.5 13.0, 10 [2–19] 0.8, 0 [0–1] 4.1, 4 [0–6]
Non-multimorbid – 13.4 36.0 6.7, 3 [0–10] 0.4, 0 [0–0] 1.3, 0 [0–2]
IBS irritable bowel syndrome, PSM psychoactive substance misuse (not alcohol), CHD coronary heart disease, COPD chronic obstructive pulmonary disease
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conditions: coronary heart disease, atrial fibrillation and
heart failure.
Validation of cluster morbidity profiles
As well as validating the clusters by their association
with patient characteristics and outcomes, the similarity
of multimorbidity clusters was compared between the
training set (80% of patients, N = 90,571) and the test set
(the other 20% of patients, N = 22,640). Results are sum-
marised below and given in full in Additional file 2: sec-
tion 4. Measures of cluster quality (i.e. entropy) were
found to be consistent between the training and test
sets.
As the training set contained more disease patterns,
the derived clusters were more comprehensive. The test
set (with fewer patients) contained fewer disease pat-
terns, and therefore, we expected the derived clusters to
be a subset of those in the training set. Indeed, valid-
ation of cluster profiles showed that every cluster in the
test set found a match in the training set. Some clusters
were particularly robust (had the smallest JSD and the
highest Pearson’s correlation coefficient), for instance,
those in the largest age strata (65–84 age strata, N = 49,
494), and clusters whose lead condition was depression,
psychoactive drug misuse or alcohol problems. A cluster
with a less clear match had the lead condition asthma in
the 18–44 age strata.
Discussion
Summary of results and comparison with other studies
This study identified and validated clusters of multimor-
bid patients using a novel patient-centred approach. In
summary, we identified 20 patient clusters across four
age strata. In the younger age-strata (18–44; 45–64), the
clusters with the highest mortality (18 times higher than
the non-multimorbid group in 18–44-year olds) com-
prised psychoactive substance abuse in combination with
alcohol problems. The clusters with the most contact
with general practice in people aged under 65 comprised
depression, anxiety and pain. In 65–84-year olds, the
cluster with the highest mortality and highest health ser-
vice use (GP contact, hospitalisations, repeat prescrip-
tions) comprised pain, coronary heart disease and
depression, and in people aged 85 or over, it comprised
heart failure, coronary heart disease and atrial fibrilla-
tion. The most common cluster in 18–44-year olds was
centred around depression, but in all other age groups,
they were centred around hypertension. In the oldest
age group, this hypertension-centred cluster was associ-
ated with the best survival and lowest health service use
among multimorbid patients. Pain featured in 13 of the
clusters.
In this study, unlike most previous analyses of multi-
morbidity, we have defined novel clusters in terms of
patients rather than diseases [10, 11]. These clusters
have practical implications for service delivery, by sup-
porting a move away from healthcare for individual dis-
eases towards the care of individuals with clusters of
conditions, and thus helping to reduce treatment burden
[29]. The high mortality of the cluster of psychoactive
substance and alcohol misuse warrants attention. The
descriptive epidemiology of this cluster (male, smoker,
under age 65, relatively low service use, from areas of
greater socioeconomic deprivation) supports the need
for better integration of substance misuse services within
primary care and need to provide improved access to
holistic management including for physical health [30].
Conversely, we found that the commonest cluster in
people aged 85 and over (58% of patients with multi-
morbidity in this age group) was associated with the
least health service use and the lowest mortality
(Table 4). This gives a more nuanced perspective on the
association of multimorbidity with age that has been
widely reported [8], in that it suggests that in the oldest
age group, multimorbidity per se may be less important,
although numerically most common. We hypothesise
that this is due to a survivor effect, i.e. individuals with
more fatal multimorbidity often do not reach this age.
Our age-stratified approach also enables different pat-
terns of co-morbidity to be identified. Thus, in younger
age groups, clusters focused around mental health are
associated with most GP contact; in people aged 65–84,
a cluster of mental health and coronary heart disease is
associated with most GP contact, and other indicators of
health service use, whereas in people aged over 85, the
cluster representing most health service contact is domi-
nated by cardiovascular conditions.
In terms of relative importance of single conditions
within multimorbid clusters, the predominance of men-
tal health conditions and hypertension has been identi-
fied in previous work [10, 11, 13, 31]. Mental health
conditions are recognised as having a major impact on
health service use over and above physical problems
[32], and our findings emphasise the importance of en-
suring psychological needs are given equal priority to
physical ones in those clusters of patients where mental
health problems are prevalent [33]. A novel finding in
our work is the inclusion of pain in many of the clusters
we identified. This aligns with studies that confirm
chronic pain is widespread and emphasises the need to
provide integrated pain management services to address
the potential adverse impact on health service use and
both physical and social functioning [34, 35].
Strengths and limitations
The robust identification of such clusters would not have
been possible without the novel use of representative data
reflecting real-world patterns of multimorbidity, age
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stratification, patient-level clustering (not requiring all pa-
tients to have identical lists of conditions) and validation
with held-out data. This is the largest-scale application of
age-stratified latent class analysis to multimorbidity, both
in patient numbers (above 100,000) and the number of
conditions (38) [11]. By including younger patients and
stratifying by age, we see how multimorbidity clusters dif-
fer over the lifecourse. Combining this with the release of
reproducible analysis scripts is an approach which we rec-
ommend for future multimorbidity clustering efforts. Our
systematic approach including all 38 conditions from Bar-
nett et al. [8], age stratification, clustering and outcomes,
was necessary to handle the complexity of multimorbidity
in healthcare.
This study suffers from typical limitations of electronic
health record research in that they rely on routine cod-
ing within the healthcare system including residual con-
founding and variable CPRD data quality. Wherever
practically feasible we have taken steps to address these,
e.g. the careful design of codelists, relying on variables
with low missingness and adjusting for key variables.
Some relevant information, such as disease severity, was
not available for the majority of diseases and so was not
modelled. This may affect the association of disease with
characteristics and outcomes. Given the observational
nature of this data, some residual confounding such as
this is inevitable, and so we caution that the relationship
between clusters, patient demographics and outcomes
should not be interpreted causally.
While the clustering approach used (LCA) is a robust
probabilistic approach, results may differ subtly if other
approaches are used. Validation of latent clusters also re-
quires further research where a larger sample size for
the test set, perhaps from another database or country,
can strengthen the validation. We notice that in every
age strata, there was a cluster whose lead condition
(pain, irritable bowel syndrome, hearing loss and asthma
respectively) had a within-cluster prevalence of less than
50%, suggesting that they are less distinctive than the
other clusters. It is also interesting that they are often
the clusters with the lowest mortality. While these were
validated in the test set, it may be that bigger datasets
are required to split these into more distinct and inter-
pretable clusters. Despite this, given the large and repre-
sentative sample, the consistency of results both
internally, across age strata and with existing literature,
we are confident in our main results. Finally, multimor-
bidity evolves over time, but we only use longitudinal
data to extract conditions in 2012 and service use and
mortality outcomes.
Conclusion
These multimorbidity clusters highlight major targets
for public health and healthcare, giving a more nuanced
understanding of multimorbidity than the work of Bar-
nett et al. [8] which rely more on simple disease counts.
The 18-fold higher mortality of younger multimorbid
patients with psychoactive substance misuse is a clear
case of an unmet need. Improving outcomes for this
neglected patient group is likely to be feasible given that
their risk factors (drug use, smoking, deprivation) are
potentially amenable to intervention. Conversely, the fact
that the majority of older multimorbid patients have
relatively low service use and mortality has implications
for the design of health services. More generally, the fact
that chronic pain is a key feature of many multimorbid-
ity clusters suggests that it is important to manage pain
within the context of multimorbidity rather than in its
own right. Similarly, our findings add to the evidence
showing the importance of mental health in multimor-
bid patients, justifying the push for parity of physical
and mental health within the healthcare system.
While patients with multimorbidity account for an
ever-increasing proportion of healthcare need and
provision [1, 4, 5, 7, 8], no existing interventions have
shown convincing evidence of benefit in improving im-
portant outcomes [9, 36]. Our findings fit with the sug-
gestion from Salisbury et al. [9] that one reason for the
failure of previous interventions is that multimorbidity is
heterogeneous, with very different diseases, needs and
outcomes in different groups of patients. Our findings
support the proposal that interventions to improve out-
comes in multimorbidity may be more appropriately tar-
geted on distinct types, and we have systematically
highlighted groups of patients where tailored approaches
could be attempted.
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